Editas Medicine, Inc.

EDIT

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001650664

E

weakest fifth of 367 graded peers in healthcare

rank 336 of 367; percentile 91.5; sampling error 2.5 points; lower is stronger


A B C D E

E, the bear




Scoreboard	
Profitability	E percentile 84.5
Solvency	D percentile 62.6
Growth and financing	C/D percentile 58.0
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $186.5M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 9, 2026 250 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$2.17 2026-11-13; market equity $334.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 84.5						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	2.0%	(6.6%)	84.5	799	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 62.6					
Twelve-month failure probability	0.12%	0.08%	56.1	245	2026-09-30
Altman Z double-prime	(29.91)	(0.31)	80.3	743	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	3.54x	2.96x	51.2	825	2025-12-31
Growth and financing, sleeve percentile 58.0					
Revenue growth, three-year compound	27.1%	10.1%	24.4	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(28.7%)	2.3%	92.1	693	2025-12-31
Net share issuance, one year	18.0%	2.4%	57.7	627	2026-02-27


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 74,107,000 USD; Altman Z is not used

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
331	Lifeward Ltd. (LFWD)	90.2	E	dilution, short runway, late filer
332	Aytu Biopharma, Inc. (AYTU)	90.4	E	fortress balance sheet
333	Q32 Bio Inc. (QTTB)	90.7	E	
334	Precision Biosciences Inc. (DTIL)	91.0	E	dilution, fortress balance sheet
335	Century Therapeutics, Inc. (IPSC)	91.3	E	dilution, fortress balance sheet
336	Editas Medicine, Inc. (EDIT)	91.5	E	fortress balance sheet
337	Beyond Air, Inc. (XAIR)	91.8	E	dilution, short runway, distress
338	Dyadic International Inc. (DYAI)	92.1	E	distress
339	Alector, Inc. (ALEC)	92.3	E	fortress balance sheet
340	Airsculpt Technologies, Inc. (AIRS)	92.6	E	late filer
341	Elutia Inc. (ELUT)	92.9	E	fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(16.6%)	(1.5%)	39
Distance from 52-week high	(42.1%)	(32.0%)	38
EBIT to enterprise value	(53.5%)	(1.8%)	13
Free cash flow yield	(49.5%)	(1.0%)	14
Book value to price	0.25	0.29	46
Sales to price	0.12	0.29	31
Composite equity issuance, five years	82.9%	19.1%	75
Relative strength against the sector, log excess return	(0.35)	(0.18)	39

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$93.2M
Operating cash flow, four quarters	-$110.2M
Months of runway	10.1
Days since last periodic filing	5 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$6.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$160.1M	2025-12-31	2026-03-09	10-K	26-000017
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$165.2M	2025-12-31	2026-03-09	10-K	26-000017
3	assets	us-gaap:Assets	$186.5M	2025-12-31	2026-03-09	10-K	26-000017
4	assets	us-gaap:Assets	$341.6M	2024-12-31	2026-03-09	10-K	26-000017
5	current assets	us-gaap:AssetsCurrent	$163.9M	2025-12-31	2026-03-09	10-K	26-000017
6	current liabilities	us-gaap:LiabilitiesCurrent	$46.2M	2025-12-31	2026-03-09	10-K	26-000017
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.6B	2025-12-31	2026-03-09	10-K	26-000017
8	operating income	us-gaap:OperatingIncomeLoss	-$160.0M	2025-12-31	2026-03-09	10-K	26-000017
9	book equity	us-gaap:StockholdersEquity	$27.3M	2025-12-31	2026-03-09	10-K	26-000017
10	liabilities	us-gaap:Liabilities	$159.2M	2025-12-31	2026-03-09	10-K	26-000017
11	total debt	us-gaap:LongTermDebt	$57.4M	2024-12-31	2025-03-05	10-K	25-000022
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$131.5M	2024-12-31	2026-03-09	10-K	26-000017
13	operating income	us-gaap:OperatingIncomeLoss	-$251.2M	2024-12-31	2026-03-09	10-K	26-000017
14	depreciation amortization	us-gaap:Depreciation	$5.8M	2024-12-31	2026-03-09	10-K	26-000017
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$40.5M	2025-12-31	2026-03-09	10-K	26-000017
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$32.3M	2024-12-31	2026-03-09	10-K	26-000017
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$78.1M	2023-12-31	2025-03-05	10-K	25-000022
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$19.7M	2022-12-31	2025-03-05	10-K	25-000022

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$607,000	2025-12-31	2026-03-09	10-K	26-000017
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$210.3M	2024-12-31	2026-03-09	10-K	26-000017
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$8.8M	2024-12-31	2026-03-09	10-K	26-000017
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$132.2M	2023-12-31	2025-03-05	10-K	25-000022
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.7M	2023-12-31	2025-03-05	10-K	25-000022
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$177.3M	2022-12-31	2025-03-05	10-K	25-000022
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.1M	2022-12-31	2025-03-05	10-K	25-000022
26	assets	us-gaap:Assets	$499.2M	2023-12-31	2025-03-05	10-K	25-000022
27	assets	us-gaap:Assets	$514.3M	2022-12-31	2024-02-28	10-K	24-000008
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	97,871,999	2026-02-27	2026-03-09	10-K	26-000017
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	82,976,284	2025-02-28	2025-03-05	10-K	25-000022

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.